Indications › Type 2 diabetes › tirzepatide
tirzepatide in type 2 diabetes
tirzepatide is approved in the US for type 2 diabetes, and has 31 trials on file here in this condition. 25 of them are phase 3 or later. The next scheduled result is 2027-02-14.
31 registered trials study tirzepatide (Zepbound, Mounjaro) in type 2 diabetes, 12 of them still active and 2 in phase 3. The next is due to report 2027-02-14.
- Trials on file
- 31
- Active
- 12
- Active phase 3
- 2
- Participants in active trials
- 5,812
- Sponsors
- 10
- Scheduled readouts
- 7
Scheduled to report
Dates are filed by the sponsor and move often. Each links to its own record and change history.
All trials on file
Every registered trial of tirzepatide grouped under type 2 diabetes, largest first. Grouping follows the registry’s own condition wording.
See the full record for tirzepatide, or every molecule being studied in type 2 diabetes. These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.